Navigating Drug Design In 'Beyond The Rule Of 5' Landscape

By Bara Townsend, Marketing Communications Specialist

Drug discovery is no longer defined by small molecules alone. A rapidly expanding landscape of modalities—from antibody-drug conjugates to gene and cell therapies—is opening new possibilities for treating complex diseases. Yet these advances come with practical hurdles around manufacturing, delivery, scalability, safety, and regulatory pathways. In this shifting environment, the enduring advantages of drug-like chemical properties, oral bioavailability, intracellular access, and scalable production, remain critical. A new generation of hybrid strategies is emerging, blending biologic precision with chemical versatility. Innovations such as protein degraders and macrocyclic peptides illustrate how biology-driven design and advanced chemistry can converge to unlock more effective therapies.

See how success in this space increasingly depends on predictive tools that can accurately guide complex design decisions.